Belite Bio (BLTE) EBITDA (2022 - 2026)
Belite Bio (BLTE) posted quarterly EBITDA of -$26.9 million for Q1 2026, down 88.79% year-over-year from -$240.2 million in Q1 2025, and up 99.89% on a QoQ basis from -$25.4 billion in Q4 2025.
Belite Bio (BLTE) EBITDA (2022 - 2026) Analysis & Trends
Belite Bio (BLTE) has reported EBITDA for 5 consecutive years, with -$26.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA fell 88.79% year-over-year to -$26.9 million; the TTM figure through Mar 2026 stood at -$63.3 billion (down 122.12% YoY), while the FY2025 annual figure was -$77.5 million, down 112.7% from the prior year.
- EBITDA came in at -$26.9 million for Q1 2026 at Belite Bio, up from -$25.4 billion in the prior quarter.
- The five-year high for EBITDA was -$6.7 million in Q4 2022, with the low at -$25.4 billion in Q4 2025.
- Average EBITDA over 5 years is -$7.4 billion, with a median of -$6.9 billion recorded in 2023.
- Across the five-year window, EBITDA tumbled 150949.87% in 2024 and soared 99.82% in 2025, its largest moves.
- Year by year, EBITDA stood at -$6.7 million in 2022, then dropped by 3.03% to -$6.9 million in 2023, then sank by 150949.87% to -$10.4 billion in 2024, then tumbled by 145.47% to -$25.4 billion in 2025, then surged by 99.89% to -$26.9 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$26.9 million, -$25.4 billion, and -$21.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Genmab A | 276,399.99 Bn | 276,398.47 Bn | 831.00 Mn | -106.00 Mn |
| 2 | Akari Therapeutics | 1,217.26 Bn | 1,217.26 Bn | - | -14.44 Mn |
| 3 | BeOne Medicines | 419.38 Bn | 414.59 Bn | 1.35 Bn | 249.90 Mn |
| 4 | Vertex Pharmaceuticals | 126.54 Bn | 119.30 Bn | 2.59 Bn | 1.14 Bn |
| 5 | Pharming | 110.17 Bn | 110.12 Bn | 65.80 Mn | -4.91 Mn |
| 6 | Regeneron Pharmaceuticals | 64.97 Bn | 56.22 Bn | 3.31 Bn | 661.60 Mn |
| 7 | Argenx Se | 56.44 Bn | 56.44 Bn | 1.18 Bn | 394.00 Mn |
| 8 | Alnylam Pharmaceuticals | 40.09 Bn | 37.08 Bn | 959.66 Mn | 201.19 Mn |
| 9 | Revolution Medicines | 37.15 Bn | 37.15 Bn | - | -445.22 Mn |
| 10 | Belite Bio | 96.77 Mn | 96.77 Mn | - | -26.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.92 Mn |
| Dec 31, 2025 | -25.43 Bn |
| Sep 30, 2025 | -21.61 Bn |
| Jun 30, 2025 | -16.19 Bn |
| Mar 31, 2025 | -14.26 Mn |
| Dec 31, 2024 | -10.36 Bn |
| Sep 30, 2024 | -8.60 Bn |
| Jun 30, 2024 | -9.50 Bn |
| Mar 31, 2024 | -7.97 Bn |
| Dec 31, 2023 | -6.86 Mn |
| Sep 30, 2023 | -10.99 Mn |
| Jun 30, 2023 | -6.89 Bn |
| Mar 31, 2023 | -6.88 Bn |
| Dec 31, 2022 | -6.66 Mn |
| Sep 30, 2022 | -2.57 Bn |
| Jun 30, 2022 | -2.57 Bn |